Eurocor Tech - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor announces presentation of Valentines Trial II results at CRT2012

Date: 2012/02/09

DIOR® drug-eluting balloon shows effective and safe treatment for de novo lesions
Treatment with DIOR® Paclitaxel-eluting balloon shows an overall TLR rate of 2.9% at 8 months post treatment

Washington DC, USA / Bonn, Germany – February 9, 2012 – Eurocor GmbH presented the eight month follow-up data from the Valentines Trial II Global Registry on February 7 during the iMPACT Trial Session at CRT2012 in Washington D.C., USA. The multi-center, international, short-term Valentines-registry was conducted with an objective to assess the efficacy of the Paclitaxel-eluting balloon DIOR® DEB for de novo lesions at 6-9 months follow-up. 103 patients suffering from de novo lesions were enrolled by 38 Investigators from 16 countries starting February 14th up to March 31st 2011. The initial eight-month follow-up data have been unveiled by Dr. Antonio Serra (Barcelona, Spain), one of the Principle Investigators (PI) during the conference. A follow-up rate of 99 % was reached with a 50.5% on-site Clinical Monitoring. The trial was carried out by three Principal Investigators: Prof. Dr. Fazila Malik (Dhaka, Bangladesh), Dr. Alfredo Rodriguez (Buenos Aires, Argentina) and Dr. Antonio Serra (Barcelona, Spain).

The Results: The eight-month results convincingly show that the DIOR® DEB is a safe and effective treatment for cases of de novo lesions. The treatment with DIOR® DEB resulted in a very low overall target lesion revascularization (TLR) rate of 2.9% and a target vessel revascularization (TVR) rate of 6.9%. Also the overall major adverse cardiac event (MACE) rate of 8.7% was remarkable low. The preliminary late lumen loss (LLL) upon angiographic follow-up of a small subset of patients was 0.30 ± 0.36 mm and 0.33 ± 0.37 mm for the in-DEB segment and traditional in-segment analyses, respectively. A subgroup analysis of the patients suffering from diabetes (28.2%) show that the DIOR® DEB is effective in this population with a single digit TLR rate of 6.9% and a TVR rate of 13.8% at 6-9 months follow-up post treatment. The non-diabetic group of patients shows a TLR rate of 1.4% and a TVR rate of 4.1% at 6-9 months follow-up.

Dr. Antonio Serra commented: “The results of the Valentines Trial II data confirm the excellent results we obtained already in the Spanish Multicenter Registry which investigated safety and efficacy of DIOR® DEB treatment for de novo lesions in small vessels. With the now available results for Valentines Trial II we could prove that this is also true for de novo lesions in vessel with diameter of ≥ 2.5mm.”

Dr. Rembert Pogge von Strandmann, Director Clinical Department said: “We are happy to see furthermore positive results and clinical evidence of our DIOR® drug-eluting balloon in several clinical studies. We are confident that our DEB technology will result in significant therapeutic advantages for the patients and show a promising alternative therapeutic treatment option in the field of vascular interventions. The DIOR® DEB can be considered as a good treatment option for patients suffering from stenotic lesions, in-stent restenose or de novo lesions.”

Detailed Trial Results available at: and

Press Release: presentation of Valentines Trial II results at CRT2012

Pressemitteilung: Eurocor präsentiert Ergebnisse des Valentines Trial II

Press Release Spain - Información de prensa

Presentation of Valentines Trial II results at CRT2012